Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in Patients Newly Initiating Glucocorticoid Therapy - Summary - MDSpire

Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in Patients Newly Initiating Glucocorticoid Therapy

  • By

  • Mai Kawazoe

  • Kaichi Kaneko

  • Shotaro Masuoka

  • Soichi Yamada

  • Zento Yamada

  • Sei Muraoka

  • Karin Furukawa

  • Hiroshi Sato

  • Eri Watanabe

  • Keiko Koshiba

  • Izumi Irita

  • Miwa Kanaji

  • Takahiko Sugihara

  • Junko Nishio

  • Toshihiro Nanki

  • November 18, 2024

  • 0 min

Share

Objective:

To compare the efficacy of romosozumab (ROMO) with denosumab (DMAb) and bisphosphonates (BP) in treating glucocorticoid-induced osteoporosis (GIOP) in patients with rheumatic diseases.

Key Findings:
  • ROMO group showed the greatest increase in lumbar spine BMD (8.6%) compared to DMAb (3.3%) and BP (-0.4%), indicating its superior efficacy.
  • Bone formation markers were slightly elevated in the ROMO group, while resorption markers decreased across all groups, suggesting a favorable bone turnover profile.
  • ROMO significantly increased lumbar spine BMD in glucocorticoid-treated patients.
Interpretation:

Romosozumab is effective in increasing lumbar spine BMD in patients undergoing glucocorticoid treatment for rheumatic diseases, suggesting it may be a beneficial alternative to existing therapies.

Limitations:
  • Small sample size with only 11 patients in the ROMO group, which may limit generalizability.
  • Open-label design may introduce bias in reporting outcomes, affecting the study's validity.
Conclusion:

Romosozumab demonstrates superior efficacy in increasing lumbar spine BMD compared to denosumab and bisphosphonates in patients starting glucocorticoid therapy for rheumatic diseases, suggesting it may be a beneficial alternative.

Original Source(s)

Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in Patients Newly Initiating Glucocorticoid Therapy

  • by Mai Kawazoe, Kaichi Kaneko, Shotaro Masuoka, Soichi Yamada, Zento Yamada, Sei Muraoka, Karin Furukawa, Hiroshi Sato, Eri Watanabe, Keiko Koshiba, Izumi Irita, Miwa Kanaji, Takahiko Sugihara, Junko Nishio, Toshihiro Nanki

  • November 18, 2024

Related Content

Evaluating the reliability and quality of osteoporosis content on TikTok and BiliBili: A cross-sectional content analysis

Lower odds of prevalent vertebral fractures with b/tsDMARD use among rheumatoid arthritis patients in clinical remission: a retrospective observational study

Raman spectroscopic fingerprinting uncovers a multi-scale structural–mechanical–transcriptomic coupling landscape in osteoporosis